Evaluation of a Monthly Coverage Maximum (Drug-Specific Quantity Limit) on the 5-HT1 Agonists (Triptans) and Dihydroergotamine Nasal Spray

BACKGROUND: Ensuring the appropriate use of migraine therapies is an important consideration for care providers, patients, employers, and managed care organizations (MCOs) because of the high cost of treatment for this fairly prevalent disabling disease. A review of utilization of serotonin 5-HT1 re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Lauren, Mayzell, George, Pedan, Alex, Farrell, Maureen, Gilbert, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2003
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437288/
https://www.ncbi.nlm.nih.gov/pubmed/14613452
http://dx.doi.org/10.18553/jmcp.2003.9.4.335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437288/
https://www.ncbi.nlm.nih.gov/pubmed/14613452
http://dx.doi.org/10.18553/jmcp.2003.9.4.335

Ejemplares similares